Immunoglobulin E (IgE) specific for Plantago lanceolata allergens (IgE (Plantago lanceolata))

Immunoglobulin E (IgE) specific for Plantago lanceolata allergens is a specialized class of antibodies that mediates Type I hypersensitivity reactions to English plantain pollen [1]. These antibodies are produced by B cells following sensitization to specific proteins within the pollen, such as the major allergen Pla l 1 [1]. Upon re-exposure, the allergens cross-link the specific IgE molecules bound to the high-affinity FcεRI receptors on mast cells and basophils, leading to the rapid release of inflammatory mediators like histamine [2]. This physiological response results in clinical symptoms including allergic rhinitis, conjunctivitis, and bronchial asthma [2]. Therapeutic intervention often involves allergen-specific immunotherapy (AIT), which seeks to desensitize the patient by inducing a shift from IgE-mediated responses to protective IgG4-mediated responses [4]. Additionally, monoclonal antibodies like omalizumab can be used to neutralize circulating IgE, thereby preventing the activation of effector cells regardless of allergen specificity [3]. Monitoring of these specific IgE levels is crucial for both diagnosis and assessing the efficacy of therapeutic interventions [4].

Other names

Anti-Plantago lanceolata IgEEnglish plantain-specific IgERibwort plantain-specific IgEIgE specific for Pla l 1IgE specific for Pla l 2IgE specific for Pla l 3IgE specific for Pla l 4IgE specific for Pla l 5sIgE (Plantago lanceolata)

Omalizumab acts as a monoclonal antibody that binds to the Fc region (Cε3 domain) of circulating IgE, preventing its binding to the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the allergic cascade [3]. Allergen-specific immunotherapy (AIT) involves the controlled administration of Plantago lanceolata extracts to induce immune tolerance, characterized by the induction of regulatory T cells (Tregs) and a shift from a Th2-dominated response to a Th1-dominated response, alongside the production of "blocking" IgG4 antibodies [4].